Research programme: third-generation antifolates - Jacobus

Drug Profile

Research programme: third-generation antifolates - Jacobus

Alternative Names: JPC 2005; JPS 2028; PS 15; PS 26; PS 33; Third-generation antifolates research programme - Jacobus; WR 250417

Latest Information Update: 24 Apr 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Jacobus Pharmaceutical
  • Developer Walter Reed Army Medical Center
  • Class
  • Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Malaria; Mycobacterium avium complex infections; Pneumocystis pneumonia

Most Recent Events

  • 16 Dec 2003 Preclinical trials in Malaria in USA (unspecified route)
  • 16 Dec 2003 Data presented at the 52nd Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH-2003) have been added to the pharmacokinetics section
  • 26 Jul 2001 No-Development-Reported for Malaria in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top